Leber - Karzinom: Studien
Sorafenib HCC Accessment Randomized Protocoll
Atezolizumab/Bevacizumab
nicht resektables HCC im intermediärem Stadium
Zusätzlich (TACE) initial oder erst bei Krankheitsprogression.
Atezolizumab-Bevacizumab to Sorafenib (4)
Atezolizumab-Bevacizumab besser
Sunitinib v Sorafenib: Sorafenib besser
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Ramucirumab (VEGFR-2- AG) bei HCC nach Sorafenib
Phase I study of tightly conformal RT for liver metastases
HCC bei Kindern: Praeoperative Platin- und Doxorubicin-haltige Chemotherapie nicht effizient.
1.) Katz A, et al.:
RTOG 0438: a phase I trial of highly conformal radiation therapy for patients with liver metastases.
J Clin Oncol 30(2012) suppl 4; abstr 257
2.) Murawski M, et al.:
Hepatocellular Carcinoma in Children: Does Modified Platinum- and Doxorubicin-Based Chemotherapy Increase Tumor Resectability and Change Outcome? Lessons Learned From the SIOPEL 2 and 3 Studies.
J Clin Oncol 2016;34:1050-1056
4.) Finn RS, Qin S, Ikeda M, et al.:
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.
N Engl J Med 382:1894-1905, 2020
